The inaugural ELRIG CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held at the King’s Centre, Oxford 27 & 28 February 2019. Genome Engineering, including Zinc-finger, TALEN and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, target validation in developing advanced cellular and in vivo disease models, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus.
More information can be found here